AlmegaPL (Nannochloropsis oculata Algae)

AlmegaPL is a marine algae oil extract from Nannochloropsis oculata containing EPA and DHA omega-3 fatty acids. It increases omega-3 index levels and supports cardiovascular health through enhanced membrane phospholipid incorporation.

Origin & History

AlmegaPL is a branded omega-3 oil derived from the microalga Nannochloropsis oculata, containing over 25% EPA (eicosapentaenoic acid) in polar lipid form without DHA. It is produced through extraction methods that yield a concentrated polar lipid-rich oil (>15% w/w) from this marine microalgae source.

Historical & Cultural Context

No historical or traditional medicine use was identified for AlmegaPL or Nannochloropsis oculata in the research. This is a modern branded extract developed specifically as a dietary supplement.

Health Benefits

• Increased Omega-3 Index by 16% (from 4.96% to 5.75%) in 12 weeks based on RCT evidence (n=104)
• Reduced total cholesterol by 3% and VLDL cholesterol by 25% in healthy adults (moderate evidence from RCT)
• Decreased triglycerides by 14.9% in normolipidemic adults (preliminary evidence from cohort study)
• Reduced hip circumference and body weight in 12-week RCT (moderate evidence)
• Improved vigor scores without raising LDL cholesterol, unlike DHA-containing sources (moderate evidence)

How It Works

AlmegaPL provides EPA and DHA fatty acids that incorporate into cell membrane phospholipids, particularly in red blood cells and cardiac tissue. These omega-3s modulate inflammatory pathways by competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing pro-inflammatory eicosanoid production. The algae-derived omega-3s also activate PPAR-alpha receptors, enhancing fatty acid oxidation and improving lipid metabolism.

Scientific Research

A 12-week double-blind RCT (n=120 randomized, 104 completers) demonstrated significant increases in Omega-3 Index and EPA levels, with reductions in total cholesterol, VLDL, and body measurements (PMC7353404). A post-market cohort study confirmed cholesterol reduction and 14.9% triglyceride decrease at 1000-1100 mg/day doses (PMID: 38379539; NCT05267301).

Clinical Summary

A randomized controlled trial (n=104) demonstrated that AlmegaPL supplementation increased omega-3 index from 4.96% to 5.75% over 12 weeks, representing a 16% improvement. The same study showed moderate evidence for 3% reduction in total cholesterol and 25% reduction in VLDL cholesterol in healthy adults. Preliminary cohort data suggests 14.9% triglyceride reduction in normolipidemic individuals. The evidence base is emerging but limited to single-study outcomes for most benefits.

Nutritional Profile

AlmegaPL (Nannochloropsis oculata microalgae extract) is characterized by a phospholipid-bound omega-3 fatty acid matrix, which distinguishes it from standard fish oil or algal oil triglyceride forms. Key bioactive components include: EPA (eicosapentaenoic acid) as the dominant omega-3, delivered primarily in phospholipid form (phosphatidylcholine and phosphatidylethanolamine bound), which enhances intestinal absorption and lymphatic transport compared to triglyceride-bound EPA — bioavailability studies suggest phospholipid-bound EPA achieves superior incorporation into red blood cell membranes and plasma at lower doses. DHA is present in minor amounts, as Nannochloropsis species are EPA-dominant. The extract also contains glycolipids and betaine lipids native to the microalgae cell membrane. Carotenoid content includes violaxanthin and zeaxanthin, both naturally occurring in Nannochloropsis oculata, with antioxidant and potential anti-inflammatory roles. Chlorophyll derivatives are present in small quantities. Protein content in the whole algae biomass is approximately 25–35% by dry weight, though the AlmegaPL extract is lipid-fraction concentrated, reducing protein contribution in the final ingredient. Mineral content from the source algae includes iodine, calcium, magnesium, and iron, though concentrations in the extracted lipid fraction are minimal. The phospholipid delivery matrix is the primary distinguishing nutritional feature, enabling lower effective doses (typically 1–1.5g/day in clinical studies) to produce measurable omega-3 index increases compared to standard fish oil formulations.

Preparation & Dosage

Clinically studied doses include 1000-1100 mg/day in capsule form. The 12-week RCT used AlmegaPL standardized to >15% polar lipids and >25% EPA w/w. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CoQ10, astaxanthin, vitamin E, magnesium, plant sterols

Safety & Interactions

AlmegaPL appears well-tolerated in clinical studies with no serious adverse events reported in the 12-week RCT. As an algae-derived omega-3 source, it may interact with anticoagulant medications like warfarin by enhancing bleeding risk, though this interaction is theoretical. Mild gastrointestinal effects such as nausea or fishy aftertaste may occur, similar to other omega-3 supplements. Pregnancy and lactation safety has not been established in clinical trials.